Publications by authors named "Janardan D Khandekar"
Genomic and personalized medicine implementation efforts have largely centered on specialty care in tertiary health systems. There are few examples of fully integrated care systems that span the healthcare continuum. In 2014, NorthShore University HealthSystem launched the Center for Personalized Medicine to catalyze the delivery of personalized medicine.
View Article and Find Full Text PDFCancer-associated thrombosis (CAT) is common and associated with mortality. We estimated CAT rate by cancer sites and inherited factors among cancer patients from the UK Biobank (N =70,406). The 12-month CAT rate after cancer diagnosis was 2.
View Article and Find Full Text PDFBackground: Studies of outpatients with mild or moderate COVID-19 are uncommon. We studied: 1) association of symptoms with reverse transcriptase polymerase chain reaction (RT-PCR) test results; and 2) association of initial RT-PCR cycle threshold (Ct) in relation to duration of RT-PCR positivity in outpatients with mild or moderate COVID-19.
Methods: This was a cohort study of outpatients with confirmed COVID-19 and at least one symptom.
Article Synopsis
- 13-Cis retinoic acid (13-CRA) was tested in a phase 3 trial to see if it could reduce second primary tumors (SPTs) and improve overall survival (OS) in patients with early-stage squamous cell cancers of the head and neck (SCCHNs).
- The study involved 176 patients who were randomly given either low-dose 13-CRA or a placebo for two years, with results showing no significant reduction in SPT incidence or improvement in OS for the overall group.
- However, certain subsets, particularly women and never/former smokers, showed trends toward better survival outcomes with 13-CRA treatment, highlighting the need for future research focused on specific risk factors and tumor characteristics.
Purpose: The LIFE Cancer Survivorship Program at NorthShore University HealthSystem provides risk-adapted visits (RAV) facilitated by an oncology nurse during which a survivorship care plan (SCP) is provided and discussed. In this report, we describe and evaluate RAV in promoting individualized health care and self-management during survivorship transition.
Methods: Patients complete a post-RAV questionnaire at their RAV and another ≥1 year after their RAV.
Background: It has been an abiding belief among geneticists that multicellular organisms' genomes can be analyzed under the assumption that a single individual has a uniform genome in all its cells. Despite some evidence to the contrary, this belief has been used as an axiomatic assumption in most genome analysis software packages. In this paper we present observations in human whole genome data, human whole exome data and in mouse whole genome data to challenge this assumption.
View Article and Find Full Text PDFThe polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), is overexpressed in several human malignancies including breast cancer. Aberrant expression of EZH2 has been associated with metastasis and poor prognosis in cancer patients. Despite the clear role of EZH2 in oncogenesis and therapy failure, not much is known about chemotherapeutics and chemopreventive agents that can suppress its expression and activity.
View Article and Find Full Text PDFPurpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine using a fixed dose rate infusion (FDRI) in combination with gefitinib in patients (pts) with pancreatic adenocarcinoma (PCa).
Patients And Methods: Patients with advanced PCa were given gemcitabine at the FDRI of 10 mg/m(2)/min IV on Days 1, 8, and 15 of a 28-day cycle. Dose levels of 1000, 1200, and 1500 mg/m(2) were evaluated.